Best Foods to Eat on GLP-1 Drugs: Protein, Muscle Loss, and What the Science Says

One of the most protein-dense foods relative to volume and caloric cost. A 200g serving of plain Greek yogurt delivers 17–20g protein at 110–140 kcal — exceptional density for someone eating 1000 kcal/day total. The casein protein in yogurt is slow-digesting, providing sustained amino acid availability for muscle protein synthesis. Full-fat Greek yogurt is appropriate if GI tolerability is a concern — fat slows gastric emptying and may reduce nausea on GLP-1 drugs. Avoid flavored varieties with added sugar, which inflate calories without nutritional benefit.

Whole eggs provide the most bioavailable protein of any whole food (biological value ~100), plus choline, B12, and fat-soluble vitamins important during caloric restriction. Two large eggs = 12g protein, 140 kcal. Egg whites add pure protein with near-zero fat or carbohydrate (3.6g protein / 17 kcal per egg white). Many GLP-1 users find eggs particularly well-tolerated compared to heavier protein sources — the lower fat content of egg whites reduces GI load during periods of nausea. Scrambled eggs with a small amount of cheese is one of the most consistently tolerated high-protein meals during GLP-1 titration.

Low-fat cottage cheese has become a staple protein food for GLP-1 users for good reason: one cup (226g) delivers 25g protein at 180 kcal. The texture is well-tolerated when nausea is present, unlike denser meats. Cottage cheese is predominantly casein protein (slow-digesting), making it particularly effective for maintaining muscle protein synthesis during the prolonged overnight fast that many GLP-1 users experience as appetite suppresses evening eating. Can be blended smooth, mixed with fruit, or used in savory preparations.

Canned fish offers an exceptional protein-to-calorie ratio, long shelf life for days when cooking feels impossible, and omega-3 fatty acids (EPA/DHA) that support the anti-inflammatory signaling relevant during metabolic adaptation. A 5oz can of light tuna in water = 25g protein, 100 kcal. Sardines in olive oil provide similar protein with additional omega-3s and vitamin D. These are particularly valuable during the titration phase when appetite is lowest and meal preparation energy is minimal. Keep several cans on hand as a reliable fallback protein source.

When whole food protein intake falls short of 1.2g/kg/day target — which is common during the first 8–12 weeks of GLP-1 therapy — protein powder bridges the gap efficiently. Whey protein isolate (25g protein / 110 kcal per serving) is the best-studied form for lean mass preservation during caloric deficit. Collagen peptides (18–20g protein per serving) support connective tissue and may have joint benefits relevant during rapid weight loss. Mix into Greek yogurt, blend into smoothies, or dissolve in warm liquids if solid food is poorly tolerated. Choose unflavored or lightly flavored varieties to avoid GI distress from artificial sweetener loads.

GLP-1 drugs slow gastric emptying. High-fat foods slow it further. The combination — fatty meats, fried foods, heavy cream sauces, fast food — significantly increases nausea, vomiting risk, and GI discomfort. This is not a permanent prohibition: once tolerability is established at a stable dose, moderate healthy fats (avocado, olive oil, nuts) are fine. During titration and in the first months of therapy, minimize fat load at individual meals. Lean protein sources, non-starchy vegetables, and small amounts of complex carbohydrates are better tolerated.

At 800–1200 kcal/day, there is no caloric room for nutritionally empty foods. Chips, crackers, sugary beverages, and processed snacks occupy caloric budget without providing protein or meaningful micronutrients. Liquid calories (juice, soda, alcohol) are particularly problematic — they do not trigger the same satiety signals as solid food, allowing passive overconsumption of sugar calories while simultaneously displacing protein-rich foods. Alcohol also impairs judgment around food choices and may potentiate hypoglycemia risk in patients with diabetes on GLP-1 therapy.